Your session is about to expire
← Back to Search
Glycine Transporter Inhibitor
Bitopertin oral dose level 1 for Schizophrenia
Phase 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
Summary
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
Eligible Conditions
- Schizophrenia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Bitopertin oral dose level 2Experimental Treatment1 Intervention
Group II: Bitopertin oral dose level 1Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bitopertin
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Hoffmann-La RocheLead Sponsor
2,457 Previous Clinical Trials
1,097,115 Total Patients Enrolled
18 Trials studying Schizophrenia
7,438 Patients Enrolled for Schizophrenia
Clinical TrialsStudy DirectorHoffmann-La Roche
2,227 Previous Clinical Trials
895,805 Total Patients Enrolled
17 Trials studying Schizophrenia
7,857 Patients Enrolled for Schizophrenia
Share this study with friends
Copy Link
Messenger